|
|
慢性肾脏病的微炎症机制和中药治疗研究进展
|
Abstract:
慢性肾脏病(chronic kidney disease, CKD)患者体内普遍存在微炎症状态，是导致CKD进展的重要危险因素之一，其产生的机制受多种因素调控，随着肾功能的下降而逐渐加重，是导致患者出现各种并发症的一种非显性炎症状态，因此缓解微炎症状态对于CKD的治疗有重要意义。目前西医缺乏治疗CKD微炎症状态行之有效的治疗手段。近几年来中医药治疗可减轻CKD患者血清炎症因子的表达，最终实现微炎症状态的整体改善。从中药单药、中药成药以及外治法等多个维度，针对CKD微炎症状态具有显著疗效，其安全性好且不良反应发生率低，能够及时控制炎症发展，有效延缓CKD的进展。该文主要探讨CKD患者微炎症状态产生的相关机制、对临床的影响及其中医药治疗的进展，更好的发挥中医药治疗的优势，为临床治疗CKD微炎症状态提供参考。
CKD patients generally have a microinflammatory state, which is one of the important risk factors leading to the progression of CKD. Its mechanism is regulated by various factors and gradually aggravates with the decline of renal function. It is a non-dominant inflammatory state leading to various complications in patients. Therefore, alleviating microinflammatory state is of great significance for the treatment of CKD. At present, Western medicine lacks effective treatment for CKD, which is complicated by microinflammation. In recent years, traditional Chinese medicine treatment has been effectively demonstrated to suppress the levels of inflammatory markers in patients with CKD, ultimately achieving an overall improvement in the microinflammatory state. From the aspects of TCM monotherapy, TCM patent medicine and external treatment, it has a significant effect on the microinflammatory state of CKD. Its safety is good, and the incidence of adverse reactions is low, which can control the development of inflammation in time and effectively delay the progress of CKD. This article mainly discusses the related mechanism of microinflammatory state in patients with CKD, its influence on clinic and the progress of TCM treatment, so as to better exert the advantages of TCM treatment and provide reference for clinical treatment of CKD complicated with microinflammatory state.
| [1] | Stevens, P.E., Ahmed, S.B., Carrero, J.J., Foster, B., Francis, A., Hall, R.K., et al. (2024) KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International, 105, S117-S314. https://doi.org/10.1016/j.kint.2023.10.018 |
| [2] | Tarun, T., Ghanta, S.N., Ong, V., Kore, R., Menon, L., Kovesdy, C., et al. (2024) Updates on New Therapies for Patients with CKD. Kidney International Reports, 9, 16-28. https://doi.org/10.1016/j.ekir.2023.10.006 |
| [3] | Anders, H. (2020) 2019 Update in Basic Kidney Research: Microbiota in Chronic Kidney Disease, Controlling Autoimmunity, Kidney Inflammation and Modelling the Glomerular Filtration Barrier. Nephrology Dialysis Transplantation, 35, 4-9. https://doi.org/10.1093/ndt/gfz219 |
| [4] | 王畅, 杨泽慧. 微炎症状态对慢性肾脏病患者的临床影响及中医治疗进展[J]. 中国中医药现代远程教育, 2020, 18(3): 66-68. |
| [5] | 白兰, 张燕, 刘鹏霄, 等. 中医药对慢性肾衰竭患者微炎症状态影响的研究现状[J]. 西部中医药, 2021, 34(9): 150-153. |
| [6] | Gao, W., Wang, X., Zou, Y., Wang, S., Dou, J. and Qian, S. (2025) Progress in the Application of Novel Inflammatory Indicators in Chronic Kidney Disease. Frontiers in Medicine, 12, Article ID: 1500166. https://doi.org/10.3389/fmed.2025.1500166 |
| [7] | 徐超, 李怡钢, 郑蜜蜜. 微炎症状态和肾功能与慢性肾功能衰竭患者合并高磷血症的关系[J]. 广西医学, 2022, 44(11): 1193-1196. |
| [8] | Rayego-Mateos, S., Marquez-Exposito, L., Basantes, P., Tejedor-Santamaria, L., Sanz, A.B., Nguyen, T.Q., et al. (2023) CCN2 Activates RIPK3, NLRP3 Inflammasome, and Nrf2/Oxidative Pathways Linked to Kidney Inflammation. Antioxidants, 12, Article No. 1541. https://doi.org/10.3390/antiox12081541 |
| [9] | White, S., Lin, L. and Hu, K. (2020) NF-κB and tPA Signaling in Kidney and Other Diseases. Cells, 9, Article No. 1348. https://doi.org/10.3390/cells9061348 |
| [10] | Xu, G., Gu, Y., Yan, N., Li, Y., Sun, L. and Li, B. (2021) Curcumin Functions as an Anti-Inflammatory and Antioxidant Agent on Arsenic-Induced Hepatic and Kidney Injury by Inhibiting MAPKs/NF-κB and Activating Nrf2 Pathways. Environmental Toxicology, 36, 2161-2173. https://doi.org/10.1002/tox.23330 |
| [11] | Mohamed, A. (2024) Anti-Inflammatory Effect of High Flux Dialyzer Surface Area 2.6 m2 in High Flux Hemodialysis and Hemodiafiltration. Egyptian journal of Immunology, 31, 184-192. https://doi.org/10.55133/eji.310119 |
| [12] | Gomółka, M., Niemczyk, L., Szamotulska, K., Mossakowska, M., Smoszna, J., Rymarz, A., et al. (2019) Biocompatibility of Hemodialysis. In: Pokorski, M., Ed., Trends in Biomedical Research, Springer International Publishing, 91-97. https://doi.org/10.1007/5584_2019_461 |
| [13] | 黄玉红, 王洁. 慢性肾脏病所致微炎症状态的研究进展[J]. 右江民族医学院学报, 2021, 43(1): 128-133. |
| [14] | Valtuille, R.A., Rossi, G. and Gimenez, E. (2021) Protective Effect of Autologous Arteriovenous Fistulae against Oxidative Stress in Hemodialyzed Patients. Cureus, 13, e15398. https://doi.org/10.7759/cureus.15398 |
| [15] | Koshida, T., Gohda, T., Sugimoto, T., Asahara, T., Asao, R., Ohsawa, I., et al. (2023) Gut Microbiome and Microbiome-Derived Metabolites in Patients with End-Stage Kidney Disease. International Journal of Molecular Sciences, 24, Article No. 11456. https://doi.org/10.3390/ijms241411456 |
| [16] | Mihai, S., Codrici, E., Popescu, I.D., Enciu, A., Albulescu, L., Necula, L.G., et al. (2018) Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome. Journal of Immunology Research, 2018, Article ID: 2180373. https://doi.org/10.1155/2018/2180373 |
| [17] | Nishiyama, K., Aono, K., Fujimoto, Y., Kuwamura, M., Okada, T., Tokumoto, H., et al. (2018) Chronic Kidney Disease after 5/6 Nephrectomy Disturbs the Intestinal Microbiota and Alters Intestinal Motility. Journal of Cellular Physiology, 234, 6667-6678. https://doi.org/10.1002/jcp.27408 |
| [18] | Noels, H., Lehrke, M., Vanholder, R. and Jankowski, J. (2021) Lipoproteins and Fatty Acids in Chronic Kidney Disease: Molecular and Metabolic Alterations. Nature Reviews Nephrology, 17, 528-542. https://doi.org/10.1038/s41581-021-00423-5 |
| [19] | Suzuki, T., Ichikawa, K., Suzuki, N., Watanabe, M. and Konta, T. (2024) Renal Tubular Damage as an Independent Risk Factor for All-Cause and Cardiovascular Mortality in a Community-Based Population: The Takahata Study. Clinical and Experimental Nephrology, 29, 444-451. https://doi.org/10.1007/s10157-024-02592-6 |
| [20] | Kamińska, J., Stopiński, M., Mucha, K., Jędrzejczak, A., Gołębiowski, M., Niewczas, M.A., et al. (2019) IL 6 but Not TNF Is Linked to Coronary Artery Calcification in Patients with Chronic Kidney Disease. Cytokine, 120, 9-14. https://doi.org/10.1016/j.cyto.2019.04.002 |
| [21] | 石肖女. 慢性肾脏病患者微炎症状态相关影响因素分析[D]: [硕士学位论文]. 长春: 吉林大学, 2014. |
| [22] | 祝青, 沈艳萍. 慢性肾脏病微炎症状态的研究进展[J]. 生命的化学, 2024, 44(4): 644-652. |
| [23] | Aguiar, L., Sá Martins, V., Pinto, I., Papoila, A., Dias, C., Figueiredo, R., et al. (2025) Nutritional Risk Assessment in Hemodialysis Patients: A Comparative Analysis of Modified Creatinine Index, Geriatric Nutritional Risk Index and Simple Protein-Energy Wasting Score with Malnutrition-Inflammation Score. Clinical Nutrition ESPEN, 66, 429-436. https://doi.org/10.1016/j.clnesp.2025.02.003 |
| [24] | 田海军, 郑艳辉, 俞燕. 慢性肾脏病微炎症状态及其中医药治疗研究进展[J]. 中医药临床杂志, 2022, 34(9): 1768-1773. |
| [25] | 范军, 武金岳. 慢性肾脏病合并微炎症状态的中医治疗研究进展[J]. 中国城乡企业卫生, 2022, 37(7): 24-28. |
| [26] | 刘子丹, 王娟, 王政, 等. 黄芪干预慢性肾脏病微炎症状态机制研究进展[J]. 环球中医药, 2025, 18(1): 192-198. |
| [27] | 魏升, 钟光辉, 曹晓丹, 等. 基于Sirt介导的NF-κB/NLRP3信号通路探讨黄芪甲苷及莪术醇对慢性肾功能衰竭大鼠的作用机制研究[J]. 新中医, 2022, 54(5): 9-13. |
| [28] | 高丙鹏, 田静, 靳银山, 等. 大黄素通过调控ROS和NLRP3炎症体通路改善草酸钙结晶诱导的肾小管上皮细胞损伤[J]. 现代泌尿外科杂志, 2021, 26(6): 525-528+540. |
| [29] | 王昉, 何伟明. 冬虫夏草治疗慢性肾脏病的中医认识及药理学研究进展[J]. 实用中医内科杂志, 2021, 35(11): 135-138. |
| [30] | 曹响, 江志雄, 徐霜霜, 等. 基于微炎症探讨中医药治疗慢性肾脏病营养不良研究进展[J]. 湖南中医杂志, 2020, 36(12): 169-171. |
| [31] | 杨克, 揭乐琴. 参乌益肾片治疗早中期慢性肾功能衰竭脾肾气阴两虚证临床研究[J]. 新中医, 2024, 56(21): 74-78. |
| [32] | 陈婷. 尿毒清颗粒对慢性肾衰竭主动脉瓣膜钙化患者氧化应激状态的影响[J]. 中国典型病例大全, 2025, 19(1): 351-354. |
| [33] | 徐磊. 肾康注射液对慢性肾脏病4期患者微炎症状态的影响[J]. 上海医药, 2018, 39(20): 18-19+22. |
| [34] | 曹斌, 王清莲. 加味参芪地黄汤治疗慢性肾衰竭疗效及对氧化应激、炎症状态的影响[J]. 现代中西医结合杂志, 2024, 33(23): 3304-3307+3311. |
| [35] | 马俊杰, 魏善斋. 真武汤中附、芍不同配伍干预持续性血液透析慢性肾脏病5期阳虚证患者临床及抗炎机制研究[J]. 辽宁中医杂志, 2019, 46(12): 2593-2596. |
| [36] | 顾威, 蒋宏. 芪蛭地龙汤对慢性肾衰竭患者微炎症状态的影响[J]. 现代中西医结合杂志, 2021, 30(20): 2239-2242. |
| [37] | 李娟, 梁萌, 胡玉清. 参芪补肾汤对慢性肾功能不全患者肾功能和微炎症状态的影响[J]. 中国中医药科技, 2020, 27(6): 859-861+892. |
| [38] | 顾雪菁, 米乐, 王文娟, 等. 补肾泄浊活血法改善非透析期慢性肾脏病患者微炎症状态的Meta分析[J]. 中国中西医结合肾病杂志, 2021, 22(4): 326-331. |
| [39] | 刘彦妍, 任永朋, 华琼. 隔姜灸联合常规疗法治疗慢性肾功能衰竭40例[J]. 中医研究, 2021, 34(8): 38-42. |
| [40] | 孙响波, 王嵩, 孙红, 等. 足三里、脾肾俞穴位埋线调控免疫紊乱改善CKD2-3期患者微炎症状态[J]. 中国中西医结合肾病杂志, 2021, 22(7): 587-590. |
| [41] | 丁保明, 梁晓平, 沈翊, 等. 和络降浊汤保留灌肠联合结肠透析对慢性肾脏病浊瘀互结证患者微炎症状态、肾功能及血清铁蛋白的影响[J]. 河北中医, 2019, 41(12): 1799-1804. |
